Retatrutide

Sale!

(198 reviews)

Retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors. It represents the next generation of multi-receptor agonists being studied for metabolic research.

Dosage

10MG

20MG

Bundles

You'll also need Bacteriostatic Water

Required to reconstitute lyophilized peptides before use in research.

Free shipping

on orders over £100

60-day money-back

guarantee

Secure checkout

256-bit SSL

3

RECEPTORS

Triple agonist

~4,700

MOLECULAR WEIGHT

Daltons

350+

STUDIES

Published research

99%+

PURITY

HPLC verified

Triple receptor agonist (GIP/GLP-1/Glucagon)
Molecular Weight: ~4700 g/mol
Appearance: White lyophilized powder
Storage: Store at -20°C
Purity: ≥99% (HPLC)
Research Use Only

Key findings from published peer-reviewed research studies.

Phase 2

Metabolic Data

Hepatic Research Findings

Triple Receptor Agonist

Phase 2 trial data published in the NEJM (2023) documented mean body weight changes as a primary metabolic endpoint, alongside measurements of HbA1c, hepatic fat content by MRI, and lipid parameters. These findings are relevant to researchers studying incretin receptor pharmacology and multi-receptor agonism mechanisms in metabolic models

Receptor Pharmacology

Triple Receptor Agonism

First triple incretin receptor agonist showing superior weight loss in Phase 2

Retatrutide’s unique triple mechanism (GIP + GLP-1 + glucagon receptors) produced mean body weight reductions of up to 24.2% at 48 weeks—the highest reported for any anti-obesity compound in clinical trials.

Metabolic Improvements

Comprehensive improvements across metabolic parameters

Beyond weight loss, subjects showed improvements in HbA1c, fasting glucose, lipid profiles, liver fat content (up to 86% reduction), and waist circumference

Liver Fat Reduction

Up to 86% reduction in liver fat content at highest dose

MRI-based assessments demonstrated dramatic hepatic fat reduction, with 93% of participants in the highest dose group achieving resolution of hepatic steatosis.

Dose-Response Relationship

Clear dose-dependent efficacy observed across all endpoints

Phase 2 data showed progressive improvements with increasing doses (1mg to 12mg), supporting the biological plausibility and receptor pharmacology of the triple agonist mechanism.

Safety information based on available preclinical and clinical data.

Mild

GI Effects

Safe

Hepatic Profile

2-4bpm

HR Increase

Gastrointestinal Effects

Most common adverse events were GI-related (nausea, diarrhea, vomiting), consistent with incretin-class agents. Dose titration helped mitigate severity.

Dose Titration

Gradual dose escalation over 12-20 weeks significantly reduced the incidence and severity of GI adverse events in clinical trials.

Cardiovascular Monitoring

Heart rate increases of 2-4 bpm observed at higher doses, consistent with GLP-1 agonist class effects. No increased cardiovascular event risk detected.

Hepatic Safety

Despite dramatic liver fat reduction, liver enzyme levels normalized rather than elevated, suggesting hepatoprotective rather than hepatotoxic effects.

Ongoing Evaluation

Phase 3 trials are underway to further characterize the long-term safety profile. Current data supports an acceptable risk-benefit ratio.

Disclaimer: This product is intended for research use only. Not for human consumption, therapeutic use, or diagnostic purposes.

Detailed chemical and physical properties.

MW

~4,700 Da

Receptors

3 (Triple)

Purity

≥99%

Phase

Phase 3

Chemical Name	Retatrutide (LY3437943)
CAS Number	2381089-83-2
Molecular Weight	~4,700 g/mol
Mechanism	Triple GIP/GLP-1/Glucagon receptor agonist
Developer	Eli Lilly and Company
Clinical Phase	Phase 3 (as of 2024)
Appearance	White to off-white lyophilized powder
Solubility	Soluble in sterile water, bacteriostatic water
Purity	≥99% (HPLC)
Endotoxin Level	<0.1 EU/mg

Common questions about Tirzepatide.

What is Retatrutide?

Retatrutide (LY3437943) is a novel first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. It represents the next evolution beyond dual agonists like tirzepatide.

How does Retatrutide differ from Tirzepatide?

While tirzepatide targets GIP and GLP-1 receptors, retatrutide adds glucagon receptor agonism. The glucagon component is believed to contribute additional energy expenditure and hepatic fat reduction benefits.

What clinical trial data is available?

Phase 2 data published in NEJM (2023) demonstrated up to 24.2% body weight reduction at 48 weeks. Phase 3 trials (TRIUMPH program) are currently ongoing.

How should Retatrutide be stored?

Store lyophilized powder at -20°C. Reconstituted solution should be stored at 2-8°C and used within 14 days. Protect from light.

What is the regulatory status of Retatrutide?

Retatrutide (LY3437943) is currently under Phase 3 clinical evaluation and holds no approval from the MHRA, FDA, or EMA for any clinical indication. This product is supplied solely for in-vitro and preclinical research purposes and must not be used in humans or animals.

Peer-reviewed publications and reference materials.

Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes

Rosenstock J, Frias JP, et al.

The Lancet (2023)

DOI: 10.1016/S0140-6736(23)01053-X

Triple-hormone-receptor agonist retatrutide for obesity (Phase 2)

Jastreboff AM, Kaplan LM, et al.

New England Journal of Medicine (2023)

DOI: 10.1056/NEJMoa2301972

GIP/GLP-1/Glucagon triple agonism: a new paradigm in metabolic medicine

Finan B, Müller TD, et al.

Molecular Metabolism (2022)

DOI: 10.1016/j.molmet.2022.101553

Related Products

Our products are strictly intended for laboratory research use only. Not for human or animal consumption. By purchasing, you confirm that you are a licensed researcher or purchasing for research purposes.